REGN - Regeneron Pharmaceuticals, Inc. (NasdaqGS)

Overview

Regeneron Pharmaceuticals, Inc. is an American biotechnology company primarily engaged in the research, development, and commercialization of pharmaceutical products for the treatment of serious medical conditions. Headquartered in Tarrytown, New York, Regeneron is a leader in the field of biopharmaceuticals, with a robust portfolio of products targeting oncology, cardiovascular diseases, and infectious diseases, among others. Significant projects include the development of Eylea, a treatment for macular degeneration, and Dupixent, a drug designed for asthma and dermatology treatments. Regeneron is also noted for its rapid development of REGEN-COV, a monoclonal antibody cocktail for COVID-19. The company's commitment to high scientific standards and rapid innovation continues to drive its success in biotechnology.

Basic Stats

The share price of Regeneron Pharmaceuticals, Inc. as of September 5, 2025 is $573.00 / share. This is a decrease of -1.33% from the prior week. The market cap (or net worth) of Regeneron Pharmaceuticals, Inc. as of September 5, 2025 is $59,659.12 MM.

The Factor Analysis chart (below right) shows a view of Regeneron Pharmaceuticals, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.

For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.

Market Cap	59,659.12 MM
EV	44,116.42 MM
Shares Out.	104.12 MM
Earnings Date
EPS (TTM)	42.82
Dividend Yield	0.61 %
Ex-Dividend Date	2025-08-18

Borrow Rate	0.41
Short Shares Avail.	2.60 MM
Short Interest	2.35 MM
Short Float	2.40 %
Days to Cover	2.96 days

Risk Free Rate	4.17 %
Price Change (1 yr)	-50.20 %
Volatility (1 yr)	0.38
Beta	0.57
Sharpe Ratio (1 yr)	-1.42
Sortino Ratio (1 yr)	-1.90

PE Ratio	13.38
Price/Book	1.99
Price/TBV	2.09
Book/Market	0.50
EBIT/EV	0.11
EBIT(3yr avg)/EV	0.11

ROA	0.12
ROE	0.16
ROIC	0.14
CROIC	0.00
OCROIC	0.15

Implied Volatility	33.09 %
Put/Call OI Ratio	0.69

Growth
Profitability
Quality Score
Value Score
Momentum Score
Stability (Low Vol) Score
Analyst Sentiment
Fund Sentiment
Insider Sentiment
Officer Sentiment
Dividend Score
QVM Score
Piotroski F-SCORE	6.00 /9

Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.

Price Target

The average one-year price target for Regeneron Pharmaceuticals, Inc. is $747.30. The forecasts range from a low of $548.43 to a high of $1,063.65. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.

Update Frequency: Monthly

Record Date	Projection Date	High	Low	Median	Average
2025-09-03	2026-09-03	1,063.65	548.43	765.00	747.30

Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for Regeneron Pharmaceuticals, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:

Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Date	Analyst	Prior	Latest Recommendation	Action
2023-01-20	JP Morgan	Neutral	Overweight	Upgrade
2023-01-24	Morgan Stanley		Overweight	Maintains
2023-01-11	EF Hutton		Buy	Maintains
2023-02-06	RBC Capital		Sector Perform	Maintains
2023-02-06	Morgan Stanley		Overweight	Maintains
2023-02-06	Baird		Neutral	Maintains
2023-02-06	SVB Leerink		Market Perform	Maintains
2022-11-11	Guggenheim		Buy	Maintains
2022-11-04	SVB Leerink		Market Perform	Maintains
2022-11-04	Piper Sandler		Overweight	Maintains
2022-11-04	Morgan Stanley		Overweight	Maintains
2022-11-01	EF Hutton		Buy	Initiate
2022-10-26	Raymond James	Market Perform	Underperform	Downgrade
2022-10-20	Cowen & Co.		Market Perform	Maintains
2022-10-17	Evercore ISI Group	Outperform	In-Line	Downgrade
2022-10-03	Goldman Sachs		Buy	Maintains
2022-09-16	Canaccord Genuity		Buy	Maintains
2022-09-13	Piper Sandler		Overweight	Maintains
2022-09-12	Wells Fargo		Overweight	Maintains
2022-09-09	SVB Leerink		Market Perform	Maintains
2022-09-09	Morgan Stanley	Equal-Weight	Overweight	Upgrade
2022-09-09	Jefferies	Underperform	Hold	Upgrade
2022-09-09	Barclays		Overweight	Maintains
2022-08-04	Morgan Stanley		Equal-Weight	Maintains
2022-08-04	BMO Capital		Outperform	Maintains
2022-07-25	SVB Leerink	Outperform	Market Perform	Downgrade
2022-07-20	Cowen & Co.		Market Perform	Maintains
2022-07-15	Morgan Stanley		Equal-Weight	Maintains
2022-06-06	Jefferies		Underperform	Initiate
2022-06-03	Wells Fargo		Overweight	Maintains
2022-06-03	Morgan Stanley		Equal-Weight	Maintains
2022-05-31	Argus Research		Buy	Maintains
2022-05-23	SVB Leerink		Outperform	Initiate
2022-05-05	RBC Capital		Sector Perform	Maintains
2022-05-05	Morgan Stanley		Equal-Weight	Maintains
2022-05-02	RBC Capital		Sector Perform	Maintains
2022-04-12	Morgan Stanley		Equal-Weight	Maintains
2022-04-12	Barclays		Overweight	Maintains
2022-02-08	Truist Securities		Buy	Maintains
2022-02-08	Oppenheimer		Outperform	Maintains
2022-02-07	Morgan Stanley		Equal-Weight	Maintains
2022-01-31	Truist Securities		Buy	Maintains
2022-01-18	Morgan Stanley		Equal-Weight	Maintains
2022-01-05	B of A Securities	Neutral	Underperform	Downgrade
2022-01-03	Bernstein	Market Perform	Outperform	Upgrade
2021-12-15	Bernstein	Outperform	Market Perform	Downgrade
2021-12-09	Wells Fargo		Overweight	Initiate
2021-12-06	Goldman Sachs		Buy	Initiate
2021-11-05	SVB Leerink		Outperform	Maintains
2021-11-05	Morgan Stanley		Equal-Weight	Maintains
2021-11-05	HC Wainwright & Co.		Buy	Maintains
2021-11-05	Benchmark	Buy	Hold	Downgrade
2021-10-26	SVB Leerink		Outperform	Maintains
2021-10-22	HC Wainwright & Co.		Buy	Maintains
2021-10-12	Morgan Stanley		Equal-Weight	Maintains
2021-09-15	HC Wainwright & Co.		Buy	Maintains
2021-09-07	Morgan Stanley		Equal-Weight	Maintains
2021-08-06	SVB Leerink		Outperform	Maintains
2021-08-06	Oppenheimer		Outperform	Maintains
2021-08-06	Barclays		Overweight	Maintains
2021-08-02	HC Wainwright & Co.		Buy	Maintains
2021-07-08	Benchmark		Buy	Maintains
2021-06-29	HC Wainwright & Co.		Buy	Initiate
2021-05-07	SVB Leerink		Outperform	Maintains
2021-05-07	Morgan Stanley		Equal-Weight	Maintains
2021-04-19	Morgan Stanley		Equal-Weight	Maintains
2021-03-26	SVB Leerink		Outperform	Maintains
2021-02-23	Credit Suisse		Outperform	Maintains
2021-02-16	Cantor Fitzgerald		Overweight	Maintains
2021-02-08	SVB Leerink		Outperform	Maintains
2021-02-08	Morgan Stanley		Equal-Weight	Maintains
2021-02-08	Credit Suisse		Outperform	Maintains
2021-02-08	Cowen & Co.		Outperform	Maintains
2021-01-25	BMO Capital	Market Perform	Outperform	Upgrade
2021-01-19	Morgan Stanley		Equal-Weight	Maintains
2021-01-14	Citigroup		Buy	Maintains
2021-01-13	Benchmark	Hold	Buy	Upgrade
2020-12-16	Morgan Stanley		Equal-Weight	Maintains
2020-12-16	Credit Suisse		Outperform	Maintains
2020-11-09	Morgan Stanley		Equal-Weight	Maintains
2020-11-06	SVB Leerink		Outperform	Maintains
2020-11-06	Credit Suisse		Outperform	Maintains
2020-11-06	BMO Capital		Market Perform	Maintains
2020-10-13	Morgan Stanley		Equal-Weight	Maintains
2020-10-06	SVB Leerink		Outperform	Maintains
2020-10-05	Cantor Fitzgerald	Neutral	Overweight	Upgrade
2020-08-20	Benchmark	Buy	Hold	Downgrade
2020-08-07	Credit Suisse		Outperform	Maintains
2020-08-06	Morgan Stanley		Equal-Weight	Maintains
2020-08-06	Citigroup		Neutral	Maintains
2020-08-06	BMO Capital		Market Perform	Maintains
2020-07-20	Credit Suisse		Outperform	Maintains
2020-07-15	Morgan Stanley		Equal-Weight	Maintains
2020-07-09	SunTrust Robinson Humphrey	Hold	Buy	Upgrade
2020-07-08	Canaccord Genuity		Buy	Maintains
2020-07-01	Oppenheimer		Outperform	Maintains
2020-06-24	Credit Suisse		Outperform	Maintains
2020-06-12	Jefferies		Buy	Maintains
2020-05-27	SVB Leerink		Outperform	Reiterate
2020-05-27	CFRA		Hold	Maintains
2020-05-26	Wells Fargo	Equal-Weight	Overweight	Upgrade
2020-05-06	SVB Leerink		Outperform	Maintains
2020-05-06	Morgan Stanley		Equal-Weight	Maintains
2020-05-06	Credit Suisse		Outperform	Maintains
2020-05-06	BMO Capital		Market Perform	Maintains
2020-05-06	Baird		Neutral	Maintains
2020-04-28	Citigroup	Buy	Neutral	Downgrade
2020-04-28	Canaccord Genuity		Buy	Maintains
2020-04-17	Benchmark	Hold	Buy	Upgrade
2020-04-15	Morgan Stanley		Equal-Weight	Maintains
2020-04-15	JP Morgan		Neutral	Maintains
2020-04-08	Benchmark		Hold	Initiate
2020-04-07	SVB Leerink		Outperform	Maintains
2020-04-06	Wells Fargo		Equal-Weight	Maintains
2020-03-12	Argus Research		Buy	Maintains
2020-03-11	Oppenheimer		Outperform	Maintains
2020-03-04	CFRA	Buy	Hold	Downgrade
2020-02-26	Credit Suisse		Outperform	Maintains
2020-02-26	Canaccord Genuity	Hold	Buy	Upgrade
2020-02-26	Baird	Outperform	Neutral	Downgrade
2020-02-25	Jefferies	Hold	Buy	Upgrade
2020-02-25	Evercore ISI Group	In-Line	Outperform	Upgrade
2020-02-11	Argus Research	Hold	Buy	Upgrade
2020-02-07	Morgan Stanley		Equal-Weight	Maintains
2020-01-17	Morgan Stanley		Equal-Weight	Maintains
2019-12-24	Raymond James		Market Perform	Initiate
2019-12-16	Evercore ISI Group	Outperform	In-Line	Downgrade
2019-12-13	Credit Suisse	Neutral	Outperform	Upgrade
2019-11-12	SunTrust Robinson Humphrey		Hold	Initiate
2019-11-07	Citigroup	Neutral	Buy	Upgrade
2019-11-06	Morgan Stanley		Equal-Weight	Maintains
2019-11-06	Credit Suisse		Neutral	Maintains
2019-11-06	BMO Capital		Market Perform	Maintains
2019-10-09	Canaccord Genuity		Hold	Maintains
2019-09-23	Guggenheim	Neutral	Buy	Upgrade
2019-08-07	Baird	Neutral	Outperform	Upgrade
2019-06-18	Argus	Buy	Hold	Downgrade
2019-05-23	Citigroup		Neutral	Maintains
2019-05-21	Credit Suisse		Neutral	Initiate
2019-05-13	Cantor Fitzgerald		Neutral	Maintains
2019-05-08	UBS		Buy	Maintains
2019-05-08	Morgan Stanley		Equal-Weight	Maintains
2019-05-08	BMO Capital		Market Perform	Maintains
2019-02-22	Guggenheim	Buy	Neutral	Downgrade
2019-01-04	Guggenheim	Neutral	Buy	Upgrade
2018-12-14	Goldman Sachs	Neutral	Buy	Upgrade
2018-10-11	Morgan Stanley	Equal-Weight	Equal-Weight	Maintains
2018-10-11	Canaccord Genuity	Hold	Hold	Maintains
2018-10-01	Cantor Fitzgerald		Neutral	Initiate
2018-08-06	Barclays	Underweight	Underweight	Maintains
2018-08-03	Morgan Stanley	Equal-Weight	Equal-Weight	Maintains
2018-08-03	Canaccord Genuity	Hold	Hold	Maintains
2018-08-03	Baird	Outperform	Neutral	Downgrade
2018-07-16	Argus	Buy	Buy	Maintains
2018-07-13	Morgan Stanley	Equal-Weight	Equal-Weight	Maintains
2018-06-27	Oppenheimer	Perform	Outperform	Upgrade
2018-05-04	Morgan Stanley	Equal-Weight	Equal-Weight	Maintains
2018-05-04	BMO Capital	Market Perform	Market Perform	Maintains
2018-05-01	Guggenheim	Buy	Neutral	Downgrade
2018-04-09	Raymond James	Outperform	Market Perform	Downgrade
2018-02-21	Canaccord Genuity	Buy	Hold	Downgrade
2018-02-09	Morgan Stanley	Equal-Weight	Equal-Weight	Maintains
2018-02-09	Leerink Swann	Outperform	Outperform	Maintains
2018-02-09	BTIG Research	Buy	Neutral	Downgrade
2018-02-09	BMO Capital	Market Perform	Market Perform	Maintains
2018-02-09	Baird	Neutral	Outperform	Upgrade
2018-01-24	JP Morgan	Neutral	Neutral	Maintains
2017-12-13	Deutsche Bank		Hold	Initiate
2017-12-01	Citigroup	Buy	Neutral	Downgrade
2017-11-28	BTIG Research	Buy	Buy	Maintains
2017-11-09	Morgan Stanley		Equal-Weight	Maintains
2017-11-09	BMO Capital		Market Perform	Maintains
2017-11-03	Baird	Underperform	Neutral	Upgrade
2017-10-20	Barclays	Equal-Weight	Underweight	Downgrade
2017-10-06	Morgan Stanley		Equal-Weight	Maintains
2017-09-21	UBS		Buy	Maintains
2017-09-15	RBC Capital		Sector Perform	Initiate
2017-08-17	Evercore ISI Group		Outperform	Initiate
2017-08-01	Baird	Neutral	Underperform	Downgrade
2017-07-10	Morgan Stanley		Equal-Weight	Maintains
2017-06-26	Bernstein	Outperform	Market Perform	Downgrade
2017-05-05	Canaccord Genuity	Hold	Buy	Upgrade
2017-03-09	UBS		Buy	Initiate
2017-02-13	PiperJaffray	Neutral	Overweight	Upgrade
2016-12-20	BMO Capital		Market Perform	Initiate
2016-12-16	BTIG Research	Neutral	Buy	Upgrade
2016-12-12	Chardan Capital	Sell	Neutral	Upgrade
2016-08-05	Baird	Outperform	Neutral	Downgrade
2016-06-29	Bernstein		Outperform	Initiate
2016-04-20	Wells Fargo	Outperform	Market Perform	Downgrade
2016-04-04	Roth Capital		Buy	Maintains
2016-04-04	Leerink Swann		Outperform	Maintains
2016-03-16	Chardan Capital	Neutral	Sell	Downgrade
2016-03-15	Gabelli & Co.		Buy	Initiate
2016-03-02	SunTrust Robinson Humphrey		Neutral	Initiate
2016-02-25	Citigroup		Buy	Initiate
2016-02-16	Chardan Capital	Sell	Neutral	Upgrade
2016-02-10	UBS		Buy	Maintains
2016-02-10	Morgan Stanley		Equal-Weight	Maintains
2016-02-10	JP Morgan		Neutral	Maintains
2016-02-10	Brean Capital		Buy	Maintains
2016-02-10	Barclays		Equal-Weight	Maintains
2016-02-05	Leerink Swann		Outperform	Initiate
2016-01-27	Canaccord Genuity	Buy	Hold	Downgrade
2016-01-25	Chardan Capital	Neutral	Sell	Downgrade
2016-01-20	Credit Suisse		Neutral	Initiate
2016-01-19	Roth Capital	Neutral	Buy	Upgrade
2016-01-07	BTIG Research		Neutral	Initiate
2015-12-04	Wells Fargo		Outperform	Initiate
2015-10-02	Morgan Stanley	Overweight	Equal-Weight	Downgrade
2015-09-07	UBS	Sell	Buy	Upgrade
2015-08-31	Chardan Capital	Buy	Neutral	Downgrade
2015-08-05	Barclays		Equal-Weight	Maintains
2015-08-04	Morgan Stanley		Overweight	Maintains
2015-08-04	Brean Capital		Buy	Maintains
2015-07-27	Jefferies		Hold	Maintains
2015-07-20	RBC Capital		Outperform	Maintains
2015-07-13	Deutsche Bank		Buy	Maintains
2015-07-09	UBS	Neutral	Sell	Downgrade
2015-06-15	RBC Capital		Outperform	Maintains
2015-06-08	Baird		Outperform	Maintains
2015-05-08	Citigroup		Buy	Maintains
2015-05-06	Leerink Swann		Outperform	Maintains
2015-03-20	Chardan Capital		Buy	Initiate
2015-02-17	Bernstein		Outperform	Initiate
2015-02-10	PiperJaffray	Overweight	Neutral	Downgrade
2015-01-14	Citigroup		Buy	Maintains
2015-01-06	Barclays		Equal-weight	Initiate
2015-01-05	Morgan Stanley	Equal-weight	Overweight	Upgrade
2014-11-21	Bank of America		Buy	Maintains
2014-11-20	Brean Capital		Buy	Maintains
2014-11-11	Argus		Buy	Maintains
2014-10-02	Guggenheim		Buy	Initiate
2014-09-02	Credit Suisse		Outperform	Maintains
2014-09-02	Brean Capital		Buy	Maintains
2014-08-05	Deutsche Bank		Buy	Maintains
2014-07-21	Argus Capital		Buy	Initiate
2014-05-07	UBS		Neutral	Maintains
2014-04-16	Canaccord Genuity		Buy	Initiate
2014-03-31	Roth Capital		Buy	Maintains
2014-03-27	Morgan Stanley		Equal-Weight	Initiate
2014-03-17	Citigroup		Buy	Upgrade
2014-02-13	Oppenheimer	Outperform	Market Perform	Downgrade
2014-02-11	Deutsche Bank		Buy	Maintains
2014-01-15	Citigroup		Neutral	Maintains
2014-01-15	BMO Capital		Market Perform	Downgrade
2013-11-27	PiperJaffray		Overweight	Initiate
2013-11-06	BMO Capital		Outperform	Maintains
2013-11-05	PiperJaffray		Overweight	Maintains
2013-11-05	Leerink Swann		Outperform	Maintains
2013-11-05	Deutsche Bank		Buy	Maintains
2013-10-01	Bank of America		Buy	Maintains
2013-09-30	PiperJaffray		Overweight	Maintains
2013-09-30	Oppenheimer		Outperform	Maintains
2013-09-30	Goldman Sachs		Buy	Maintains
2013-09-13	RBC Capital		Outperform	Maintains
2013-09-13	Lazard		Buy	Maintains
2013-08-21	Oppenheimer		Outperform	Initiate
2013-08-06	PiperJaffray		Overweight	Maintains
2013-07-12	Lazard	Neutral	Buy	Upgrade
2013-07-01	PiperJaffray	Neutral	Overweight	Upgrade
2013-05-03	Brean Capital	Hold	Buy	Upgrade
2013-05-01	Goldman Sachs		Buy	Maintains
2013-04-12	Bank of America		Buy	Maintains
2013-04-09	Goldman Sachs		Buy	Maintains
2013-03-28	JMP Securities		Market Perform	Initiate
2013-02-28	Barclays		Overweight	Initiate
2013-01-17	Brean Capital	Buy	Hold	Downgrade
2013-01-15	Jefferies	Buy	Hold	Downgrade
2012-11-12	Credit Suisse		Outperform	Initiate
2012-10-25	Deutsche Bank		Buy	Maintains
2012-10-24	Jefferies		Buy	Maintains
2012-10-24	Goldman Sachs		Buy	Maintains
2012-10-24	Deutsche Bank		Buy	Maintains
2012-10-24	Citigroup		Neutral	Maintains
2012-09-24	PiperJaffray		Neutral	Maintains
2012-09-24	Bank of America		Buy	Maintains
2012-09-17	Goldman Sachs		Buy	Maintains
2012-08-28	Bank of America		Buy	Maintains
2012-07-25	PiperJaffray		Neutral	Maintains
2012-07-25	BMO Capital	Market Perform	Outperform	Upgrade
2012-05-29	Bank oferica		Buy	Maintains
2012-05-09	Jefferies		Buy	Maintains
2012-05-09	Goldman Sachs		Buy	Maintains
2012-05-08	Bank oferica		Buy	Maintains
2012-04-27	Jefferies		Buy	Maintains
2012-04-26	PiperJaffray		Neutral	Maintains
2012-04-26	Brean Capital		Buy	Maintains
2012-04-23	Bank oferica		Buy	Maintains
2012-03-27	Bank oferica		Buy	Maintains
2012-02-14	Bank oferica		Buy	Maintains
2012-02-13	PiperJaffray		Neutral	Maintains
2023-01-30	Cowen & Co.	Market Perform	Outperform	Upgrade
2023-02-08	EF Hutton		Buy	Maintains
2023-02-17	Wells Fargo		Overweight	Maintains
2023-02-21	Wells Fargo		Overweight	Maintains
2023-02-24	EF Hutton		Buy	Reiterate
2023-03-09	RBC Capital		Sector Perform	Maintains
2023-03-14	BMO Capital		Outperform	Maintains
2023-03-24	BMO Capital		Outperform	Maintains
2023-03-24	Wells Fargo		Overweight	Maintains
2023-03-24	Baird		Neutral	Maintains
2023-03-24	Barclays		Overweight	Maintains
2023-03-24	Raymond James	Underperform	Market Perform	Upgrade
2023-03-24	Jefferies	Hold	Buy	Upgrade
2023-03-23	Raymond James	Underperform	Market Perform	Upgrade
2023-03-23	EF Hutton		Buy	Maintains
2023-03-27	SVB Leerink	Market Perform	Outperform	Upgrade
2023-03-28	Erste Group		Buy	Reiterate
2023-03-29	B of A Securities		Underperform	Maintains
2023-03-31	JP Morgan		Overweight	Maintains
2023-05-16	RBC Capital	Sector Perform	Sector Perform	Reiterate
2023-04-20	TD Cowen		Outperform	Maintains
2023-05-05	Morgan Stanley		Overweight	Maintains
2023-05-05	RBC Capital		Sector Perform	Maintains
2023-05-01	EF Hutton		Buy	Reiterate
2023-05-08	Guggenheim		Buy	Maintains
2023-05-03	Truist Securities		Buy	Maintains
2023-06-09	RBC Capital	Sector Perform	Sector Perform	Maintains
2023-06-28	Truist Securities	Buy	Buy	Maintains
2023-06-28	Baird	Neutral	Neutral	Maintains
2023-06-28	RBC Capital	Sector Perform	Sector Perform	Maintains
2023-06-28	Barclays	Overweight	Overweight	Maintains
2023-06-28	Canaccord Genuity	Buy	Hold	Downgrade
2023-06-23	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2023-06-20	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2023-10-11	Morgan Stanley	Overweight	Overweight	Maintains
2023-08-16	Truist Securities	Buy	Buy	Reiterate
2023-08-21	Canaccord Genuity	Hold	Buy	Upgrade
2023-08-21	Wells Fargo	Overweight	Overweight	Maintains
2023-08-21	Truist Securities	Buy	Buy	Reiterate
2023-08-21	Oppenheimer	Outperform	Outperform	Maintains
2023-08-21	BMO Capital	Outperform	Outperform	Maintains
2023-08-21	RBC Capital	Sector Perform	Sector Perform	Maintains
2023-08-21	Barclays	Overweight	Overweight	Maintains
2023-11-03	Morgan Stanley	Overweight	Overweight	Maintains
2023-11-03	Raymond James	Market Perform	Outperform	Upgrade
2023-08-04	Oppenheimer	Outperform	Outperform	Maintains
2023-06-27	Truist Securities	Buy	Buy	Reiterate
2023-06-27	RBC Capital	Sector Perform	Sector Perform	Reiterate
2023-08-04	RBC Capital	Sector Perform	Sector Perform	Maintains
2023-08-04	Morgan Stanley	Overweight	Overweight	Maintains
2023-12-18	Truist Securities	Buy	Buy	Reiterate
2023-07-06	Cantor Fitzgerald	Neutral	Neutral	Maintains
2023-07-17	Guggenheim	Buy	Buy	Maintains
2024-02-27	RBC Capital	Outperform	Outperform	Maintains
2023-10-16	Cantor Fitzgerald	Neutral	Neutral	Maintains
2023-07-11	Morgan Stanley	Overweight	Overweight	Maintains
2023-11-03	RBC Capital	Sector Perform	Sector Perform	Maintains
2023-08-07	Barclays	Overweight	Overweight	Maintains
2023-10-12	RBC Capital	Sector Perform	Sector Perform	Maintains
2023-08-18	Canaccord Genuity	Hold	Hold	Maintains
2023-09-15	WestPark Capital		Hold	Initiate
2023-11-03	Piper Sandler	Overweight	Overweight	Maintains
2023-12-06	TD Cowen	Outperform	Outperform	Maintains
2023-11-09	Deutsche Bank		Hold	Initiate
2023-09-15	Argus Research	Buy	Buy	Maintains
2023-09-21	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2023-11-28	Truist Securities	Buy	Buy	Reiterate
2023-11-28	Jefferies	Buy	Buy	Maintains
2024-02-06	Cantor Fitzgerald	Neutral	Neutral	Maintains
2023-11-29	Truist Securities	Buy	Buy	Reiterate
2024-05-03	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2024-04-17	UBS	Buy	Buy	Maintains
2024-06-04	RBC Capital	Outperform	Outperform	Maintains
2024-03-11	Bernstein		Outperform	Initiate
2024-02-05	BMO Capital	Outperform	Outperform	Maintains
2024-03-26	Truist Securities	Buy	Buy	Maintains
2024-02-05	RBC Capital	Outperform	Outperform	Maintains
2024-04-15	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2024-03-12	Bernstein		Outperform	Initiate
2024-01-23	Barclays	Overweight	Overweight	Maintains
2024-01-12	RBC Capital	Sector Perform	Outperform	Upgrade
2024-04-12	B of A Securities	Underperform	Underperform	Maintains
2024-04-09	RBC Capital	Outperform	Outperform	Reiterate
2024-04-03	Truist Securities	Buy	Buy	Maintains
2024-01-29	RBC Capital	Outperform	Outperform	Reiterate
2024-04-24	TD Cowen	Buy	Buy	Maintains
2024-05-14	Evercore ISI Group		Outperform	Initiate
2024-03-13	Morgan Stanley	Overweight	Overweight	Maintains
2024-04-17	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2024-01-09	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2024-06-12	RBC Capital	Outperform	Outperform	Maintains
2024-06-27	Canaccord Genuity	Buy	Buy	Maintains
2024-07-11	Morgan Stanley	Overweight	Overweight	Maintains
2024-06-25	Argus Research	Buy	Buy	Maintains
2024-07-10	Barclays	Overweight	Overweight	Maintains
2024-06-24	RBC Capital	Outperform	Outperform	Reiterate
2024-06-17	JP Morgan	Overweight	Overweight	Maintains
2024-10-16	Truist Securities	Buy	Buy	Maintains
2024-07-19	Piper Sandler	Overweight	Overweight	Maintains
2024-07-18	Guggenheim	Buy	Buy	Maintains
2025-01-27	Piper Sandler	Overweight	Overweight	Maintains
2025-01-14	Citigroup	Neutral	Neutral	Maintains
2025-04-23	Truist Securities	Buy	Buy	Maintains
2025-01-28	Citigroup	Neutral	Neutral	Maintains
2024-08-02	JP Morgan	Overweight	Overweight	Maintains
2024-08-02	RBC Capital	Outperform	Outperform	Maintains
2024-08-02	Barclays	Overweight	Overweight	Maintains
2024-08-02	Wells Fargo	Overweight	Overweight	Maintains
2024-08-02	Guggenheim	Buy	Buy	Maintains
2024-08-02	Truist Securities	Buy	Buy	Reiterate
2024-11-14	Citigroup		Neutral	Initiate
2024-10-25	RBC Capital	Outperform	Outperform	Reiterate
2025-02-05	Baird	Neutral	Neutral	Maintains
2025-02-05	Leerink Partners	Market Perform	Outperform	Upgrade
2024-09-17	RBC Capital	Outperform	Outperform	Reiterate
2024-09-16	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2024-11-15	Wolfe Research		Outperform	Initiate
2024-10-23	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2024-07-22	Cantor Fitzgerald	Neutral	Neutral	Maintains
2025-04-30	UBS	Neutral	Neutral	Maintains
2025-04-30	Baird	Neutral	Neutral	Maintains
2024-11-01	Truist Securities	Buy	Buy	Maintains
2024-11-01	BMO Capital	Outperform	Outperform	Maintains
2024-11-01	Barclays	Overweight	Overweight	Maintains
2024-11-01	RBC Capital	Outperform	Outperform	Maintains
2024-11-01	Morgan Stanley	Overweight	Overweight	Maintains
2024-11-01	Piper Sandler	Overweight	Overweight	Maintains
2024-11-06	Oppenheimer	Outperform	Outperform	Maintains
2024-08-23	Piper Sandler	Overweight	Overweight	Maintains
2024-07-23	TD Cowen	Buy	Buy	Maintains
2024-10-23	Barclays	Overweight	Overweight	Maintains
2024-10-22	Wells Fargo	Overweight	Overweight	Maintains
2024-10-22	RBC Capital	Outperform	Outperform	Reiterate
2025-03-31	JP Morgan	Overweight	Overweight	Maintains
2025-01-10	Wells Fargo	Overweight	Overweight	Maintains
2025-01-16	UBS	Buy	Neutral	Downgrade
2024-10-04	RBC Capital	Outperform	Outperform	Maintains
2024-10-24	Evercore ISI Group	Outperform	Outperform	Maintains
2024-10-24	JP Morgan	Overweight	Overweight	Maintains
2025-04-30	BMO Capital	Outperform	Outperform	Maintains
2025-04-30	Wells Fargo	Overweight	Overweight	Maintains
2025-04-30	RBC Capital	Outperform	Outperform	Maintains
2025-04-30	Goldman Sachs	Buy	Buy	Maintains
2025-04-30	Truist Securities	Buy	Buy	Maintains
2024-09-05	RBC Capital	Outperform	Outperform	Reiterate
2024-09-23	Wells Fargo	Overweight	Overweight	Reiterate
2025-01-08	Truist Securities	Buy	Buy	Maintains
2024-12-10	B of A Securities		Underperform	Reiterate
2025-04-17	B of A Securities	Underperform	Underperform	Maintains
2024-09-09	Cantor Fitzgerald	Neutral	Neutral	Reiterate
2024-09-09	RBC Capital	Outperform	Outperform	Maintains
2024-09-24	BMO Capital	Outperform	Outperform	Reiterate
2024-09-24	RBC Capital	Outperform	Outperform	Maintains
2024-09-24	Truist Securities	Buy	Buy	Reiterate
2024-09-24	Leerink Partners	Outperform	Market Perform	Downgrade
2025-01-07	Bernstein	Outperform	Outperform	Maintains
2025-04-25	Baird	Neutral	Neutral	Maintains
2024-12-17	Canaccord Genuity		Hold	Initiate
2025-04-22	Canaccord Genuity	Buy	Buy	Maintains
2025-07-10	Morgan Stanley	Overweight	Overweight	Maintains
2025-04-14	Goldman Sachs	Buy	Buy	Maintains
2025-04-17	Canaccord Genuity	Hold	Hold	Maintains
2025-05-30	Wells Fargo	Overweight	Equal-Weight	Downgrade
2025-05-01	Guggenheim	Buy	Buy	Maintains
2025-05-14	Citigroup	Neutral	Buy	Upgrade
2025-06-05	UBS	Neutral	Neutral	Maintains
2025-06-02	Citigroup	Buy	Buy	Maintains
2025-06-02	BMO Capital	Outperform	Outperform	Maintains
2025-06-02	Morgan Stanley	Overweight	Overweight	Maintains
2025-06-09	JP Morgan	Overweight	Overweight	Maintains
2025-08-27	Bernstein	Outperform	Outperform	Maintains
2025-08-27	Jefferies	Buy	Buy	Maintains
2025-07-11	UBS	Neutral	Neutral	Maintains
2025-05-27	RBC Capital	Outperform	Outperform	Reiterate
2025-07-23	Canaccord Genuity	Buy	Buy	Maintains
2025-08-04	Morgan Stanley	Overweight	Overweight	Maintains
2025-08-04	Guggenheim	Buy	Buy	Maintains
2025-08-04	BMO Capital	Outperform	Outperform	Maintains
2025-08-04	RBC Capital	Sector Perform	Sector Perform	Maintains
2025-08-11	Truist Securities	Buy	Buy	Maintains

MX:REGN
IT:1REGN	€490.80
AT:REGN
GB:0R2M
DE:RGO	€484.80
PE:REGN

REGN - Regeneron Pharmaceuticals, Inc. (NasdaqGS) - Share Price and News

Overview

Basic Stats

Price Target

Stock Upgrades/Downgrades

Other Listings